BridgeBio Pharma News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

13.12.24	BridgeBio Pharma Announces CHMP's Positive Recommendation Of Acoramidis - Quick Facts (RTTNews)
24.11.24	BridgeBio Pharma : FDA Approves Heart Disease Drug 'acoramidis' (RTTNews)
30.10.24	Biotech Stocks Facing FDA Decision In November 2024 (RTTNews)
24.10.24	BridgeBio Pharma Presents Positive Data From CANaspire Phase 1/2 Study In Canavan Disease (RTTNews)
17.09.24	BridgeBio Says FDA Grants Breakthrough Therapy Designation To Oral Infigratinib For Achondroplasia (RTTNews)
11.09.24	BridgeBio Pharma Stops Development Of BBP-631 For Congenital Adrenal Hyperplasia (RTTNews)
11.09.24	BridgeBio's BBP-812 Canavan Disease Gene Therapy Receives FDA RMAT Designation (RTTNews)
18.06.24	BridgeBio's BBP-418 Gets FDA Rare Pediatric Disease Designation For Treatment Of LGMD2I/R9 (RTTNews)
06.03.24	BridgeBio Pharma Prices Offering Of $250 Mln Of Shares (RTTNews)
05.03.24	BridgeBio Pharma Commences Public Offering Of $250 Mln Of Shares; Stock Down (RTTNews)
04.03.24	BridgeBio Grants Bayer Exclusive License To Commercialize Acoramidis To Treat ATTR-CM In Europe (RTTNews)
05.02.24	BridgeBio Announces FDA Acceptance Of NDA For Acoramidis (RTTNews)
02.02.24	BridgeBio Pharma Shares Positive Results From Phase 3 Study Of Acoramidis In ATTR-CM (RTTNews)
18.01.24	BridgeBio Climbs 4% On Strategic Investment From Blue Owl, CPP Investments (RTTNews)
18.01.24	BridgeBio Pharma Gets Up To $1.25 Bln Of Capital From Blue Owl, CPP Investments (RTTNews)
03.01.24	BridgeBio Pharma's IND Application For BBO-8520 Gets FDA Clearance (RTTNews)
05.12.23	BridgeBio Pharma Announces NDA Submission For Acoramidis - Quick Facts (RTTNews)
25.09.23	BridgeBio Pharma Announces $250 Mln PIPE Financing (RTTNews)
17.07.23	BridgeBio Pharma Reports Positive Results From Phase 3 Study Of Acoramidis; Stock Up (RTTNews)
08.03.23	BridgeBio Pharma Prices 8.823 Mln Public Offering At $17 Per Share (RTTNews)
25.07.22	EMA's Committee Says Nulibry Is Authorizable For Treating MoCD Type A: Sentynl Therapeutics (RTTNews)
25.07.22	BridgeBio Pharma and Sentynl Therapeutics Receive Positive CHMP Opinion for NULIBRY® (fosdenopterin) for the Treatment of MoCD Type A (PR Newswire)
22.06.22	BridgeBio?Pharma: Early CANaspire Trial Results Show Potential Of BBP-812 (RTTNews)
24.03.22	Pre-market Movers: MFH, ESOA, COOK, FSRD, ALLG… (RTTNews)
25.01.22	Atomwise Strengthens its Management Team, Adds Veteran Biopharma Leader David Thomson, Ph.D. as Chief Scientific Officer and Two Additional Senior Appointments (PR Newswire)
27.12.21	BridgeBio Pharma: ATTRibute-CM Study Fails To Meet Primary Endpoint At Month 12 (RTTNews)
19.11.21	BridgeBio Pharma and Helsinn Group Announce Strategic Collaboration to Co-Develop and Co-Commercialize BridgeBio’s Novel GPX4 Inhibitor in Multiple Cancer Tumor Types (GlobeNewswire)
04.11.21	BridgeBio Pharma Reports Third Quarter 2021 Financial Results and Business Update (PR Newswire)
03.11.21	BridgeBio Pharma Announces Dosing of First Patient in Phase 1/2 Trial of Investigational Gene Therapy for Canavan Disease (PR Newswire)
29.10.21	BridgeBio Pharma Announces Collaborations with Columbia University and Mount Sinai to Develop Potential Therapies for Genetic Diseases and Cancers (PR Newswire)
25.10.21	BridgeBio Pharma, Inc. Appoints Pioneering National Leader in Genomics and Workforce Diversity Hannah Valantine to its Board of Directors (PR Newswire)
12.10.21	BridgeBio Pharma Announces Progress in its KRAS Portfolio, New Gene Therapy Programs, and Updates on Advancements Across its R&D Pipeline Targeting Genetic Diseases and Cancers (PR Newswire)
07.10.21	BridgeBio Pharma Announces First Publication of Preclinical Data for its Potentially Best-in-Class SHP2 Inhibitor Designed for Treatment of Resistant Cancer, Showing Response in Established Non-sm... (PR Newswire)
06.10.21	BridgeBio Pharma to Host Virtual R&D Day on October 12, 2021 (PR Newswire)
01.10.21	BridgeBio Pharma Announces Updated Phase 2B Data for Encaleret in Autosomal Dominant Hypocalcemia Type 1 (ADH1) Demonstrating Blood and Urine Calcium Normalization in Trial Participants (PR Newswire)
15.09.21	BBIO : FDA Grants Fast Track Designation For Therapy To Treat Limb-girdle Muscular Dystrophy Type 2i (RTTNews)
15.09.21	BridgeBio Pharma Receives FDA Fast Track Designation for Investigational Therapy for the Treatment of Limb-girdle Muscular Dystrophy Type 2i (LGMD2i) (PR Newswire)
08.09.21	BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
18.08.21	BridgeBio Pharma, Inc. Appoints Finance and Pharmaceutical Leaders Fred Hassan, Andrea Ellis and Douglas Dachille to its Board of Directors (PR Newswire)
05.08.21	BridgeBio Pharma, Inc. Reports Second Quarter 2021 Financial Results and Business Update (PR Newswire)
27.07.21	BridgeBio, Bristol Myers To Study BBP-398 In Combination With OPDIVO In Advanced Solid Tumors (RTTNews)
27.07.21	BridgeBio Announces Clinical Collaboration with Bristol Myers Squibb to Study BBP-398, a Potentially Best-in-class SHP2 Inhibitor, in Combination with OPDIVO® (nivolumab) in Advanced Solid Tumors ... (PR Newswire)
12.07.21	BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
08.07.21	BridgeBio Pharma Announces Collaborations with Three Academic Research Institutions (PR Newswire)
28.05.21	BridgeBio Pharma’s Affiliate QED Therapeutics and Partner Helsinn Group Announce FDA Approval of TRUSELTIQ™ (infigratinib) for Patients with Cholangiocarcinoma (GlobeNewswire)
14.05.21	BridgeBio Gets FDA Fast Track Designation For Gene Therapy For Congenital Adrenal Hyperplasia (RTTNews)
01.03.21	BridgeBio : FDA Approves NULIBRY To Reduce Risk Of Mortality In Patients With MoCD Type A (RTTNews)
06.10.20	GSK, AZN 1st To Use NVDA's Supercomputer, IOVA To Delay BLA Filing, YMAB Plunges, GLYC On Watch (RTTNews)
05.10.20	BridgeBio To Buy All Remaining Stake In Eidos In $175 Mln Deal (RTTNews)
22.09.20	ABIO Joins Battle Against COVID-19, ERYP On Watch, LPCN To Report NASH Study Results In Q1 (RTTNews)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Roche Hldg G	255.50	0.75 %	K V
Nestle	74.88	0.62 %	K V
CieFinRichemont	137.90	0.40 %	K V
Swiss Life Hldg	699.60	0.32 %	K V
Swisscom	504.50	0.30 %	K V
Sika	215.80	-0.37 %	K V
Givaudan	3’966.00	-0.40 %	K V
Lonza Grp	535.80	-0.41 %	K V
Geberit	514.60	-0.46 %	K V
ABB	49.07	-0.95 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu BridgeBio Pharma Inc Registered Shs

Aktien Top/Flop

Meistgelesene Nachrichten